Neuropeptide Y receptor subtypes, Y1 and Y2.
Heterogeneity among NPY (and PYY) receptors was first proposed on the basis of studies on sympathetic neuroeffector junctions, where NPY (and PYY) can exert three types of action: 1) a direct (e.g., vasoconstrictor) response; 2) a postjunctional potentiating effect on NE-evoked vasoconstriction; and 3) a prejunctional suppression of stimulated NE release; the two latter phenomena are probably reciprocal, since NE affect NPY mechanisms similarly. It was found that amidated C-terminal NPY (or PYY) fragments, e.g., NPY 13-36, could stimulate selectively prejunctional NPY/PYY receptors, which were termed Y2-receptors. Consequently, the postjunctional receptors which were activated poorly by NPY/PYY fragments, were termed Y1-receptors. Later work has indicated that the Y2-receptor may occur postjunctionally in selected sympathetic effector systems. The central nervous system appears to contain a mixture of Y1- and Y2-receptors as indicated by functional as well as binding studies. For instance, NPY and NPY 13-36 produced diametrically opposite effects on behavioral activity, indicating the action of the parent peptide on two distinct receptors. Cell lines, most importantly neuroblastomas, with exclusive populations of Y1- or Y2-receptors, have been characterized by binding and second messenger studies. In this work, selective agonists for the two receptor subtypes were used. Work of many investigators has formed the basis for subclassifying NPY/PYY effects being mediated by either Y1- or Y2-receptors. A preliminary subclassification based on effects of NPY, PYY, fragments and/or analogs is provided in Table 6. It is, however, to be expected that further receptor heterogeneity will be revealed in the future. It is argued that mast cells possess atypical NPY/PYY receptors. The histamine release associated with stimulation of the latter receptors may, at least in part, underlie the capacity of NPY as well as of short C-terminal fragments to reduce blood pressure. Fragments, such as NPY 22-36, appear to be relatively selective vasodepressor agents because of their weak vasopressor properties.(ABSTRACT TRUNCATED AT 400 WORDS)
Wahlestedt
C
C
Department of Neurology and Neuroscience, Cornell University Medical College, New York, New York 10021.
Grundemar
L
L
Håkanson
R
R
Heilig
M
M
Shen
G H
GH
Zukowska-Grojec
Z
Z
Reis
D J
DJ
D002118:Calcium / Q000502:physiology; D003001:Cloning, Molecular; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D066298:In Vitro Techniques; D009447:Neuroblastoma / Q000378:metabolism; D009478:Neuropeptide Y / Q000494:pharmacology / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D010446:Peptide Fragments / Q000378:metabolism; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology; D017476:Receptors, Neuropeptide Y; D017981:Receptors, Neurotransmitter / Q000145:classification* / Q000187:drug effects; D011957:Receptors, Opioid / Q000187:drug effects; D017478:Receptors, Phencyclidine; D017480:Receptors, sigma; D015398:Signal Transduction; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects
D009478:Neuropeptide Y; D010446:Peptide Fragments; D010455:Peptides; D017476:Receptors, Neuropeptide Y; D017981:Receptors, Neurotransmitter; D011957:Receptors, Opioid; D017478:Receptors, Phencyclidine; D017480:Receptors, sigma; D019894:Peptide YY; D005576:Colforsin; D000242:Cyclic AMP; D002118:Calcium; D009638:Norepinephrine